 |
|
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
Clin Mol Hepatol. 2023;29(3):693-704. Published online 2023 Mar 9 DOI: https://doi.org/10.3350/cmh.2022.0330
|
|
Citations to this article as recorded by
 Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials
Nuttaya Wachiraphansakul, Thanawat Vongchaiudomchoke, Worapaka Manosroi, Surapon Nochaiwong, Saifur R. Chowdhury
PLOS ONE.2024; 19(2): e0297488. CrossRef Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Aditya Viswanath, Sherouk Fouda, Cornelius James Fernandez, Joseph M Pappachan
World Journal of Hepatology.2024; 16(2): 152. CrossRef The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef
|